Literature DB >> 11836698

Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom.

David R Scott1, Bjorn Hagmar, Peter Maddox, Anders Hjerpe, Joakim Dillner, Jack Cuzick, Mark E Sherman, Mark H Stoler, Robert J Kurman, Nancy B Kiviat, M Michele Manos, Mark Schiffman.   

Abstract

BACKGROUND: Human papillomavirus (HPV) DNA testing may be useful in clarifying equivocal cervical cytologic interpretations. One application might be to standardize the meaning of equivocal interpretations from laboratories in various regions. Because international differences may be particularly marked, international comparisons of emerging data will require clear translations of "equivocal" and similar terms.
METHODS: To perform a three-country comparison, the authors selected a morphologically diverse set of 188 conventional Papanicolaou tests initially classified as "squamous atypia" from a study of more than 20,000 women in Portland, Oregon (1989-1990). Previously, five U.S. expert cytopathologists independently interpreted the slides with screening cytotechnologists' marks in place. For this comparison, one British and two Scandinavian reviewers involved in HPV research reviewed the slides after original marks had been removed. The authors compared all eight reviewers' classifications of negative, equivocal, or abnormal in a series of pairwise comparisons using the kappa statistic. They then compared cytologic interpretations with HPV DNA testing.
RESULTS: Oncogenic HPV DNA detection was significantly associated with increasingly abnormal interpretations for each reader. The British reader tended to rate tests as more abnormal than the American pathologists did, whereas the Scandinavians tended to rate tests as more normal. Reference to the HPV DNA standard clarified the tendency of readers to render systematically more or less severe interpretations. For example, the Scandinavian cytologists discounted subtle (often HPV-associated) changes in favor of cytologic certainty, making HPV triage of equivocal tests less applicable there.
CONCLUSIONS: International research on cytopathology, particularly on the possible uses of HPV DNA testing, will require calibration of local cytologic definitions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836698     DOI: 10.1002/cncr.10317

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Interrater agreement of anal cytology.

Authors:  Teresa M Darragh; Diane Tokugawa; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Brandon J LaMere; Lauren Schwartz; Julia C Gage; Barbara Fetterman; Thomas Lorey; Nicolas Wentzensen
Journal:  Cancer Cytopathol       Date:  2012-07-18       Impact factor: 5.284

2.  Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007.

Authors:  Sheila Weinmann; Andrew E Williams; Aruna Kamineni; Diana S M Buist; Erin E Masterson; Natasha K Stout; Azadeh Stark; Tyler R Ross; Christopher L Owens; Terry S Field; Chyke A Doubeni
Journal:  Cancer       Date:  2015-05-18       Impact factor: 6.860

3.  Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.

Authors:  Ameli Tropé; Katrine D Sjøborg; Mari Nygård; Kjetil Røysland; Suzanne Campbell; G Cecilie Alfsen; Christine M Jonassen
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

4.  Using biomarkers as objective standards in the diagnosis of cervical biopsies.

Authors:  Mary T Galgano; Philip E Castle; Kristen A Atkins; William K Brix; Sarah R Nassau; Mark H Stoler
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

5.  Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.

Authors:  Mark Schiffman; Kai Yu; Rosemary Zuna; S Terence Dunn; Han Zhang; Joan Walker; Michael Gold; Noorie Hyun; Greg Rydzak; Hormuzd A Katki; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2016-10-17       Impact factor: 7.396

6.  Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme.

Authors:  Mari Nygård; Kjetil Røysland; Suzanne Campbell; Joakim Dillner
Journal:  BMJ Open       Date:  2014-01-08       Impact factor: 2.692

7.  Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.

Authors:  Maria Persson; K Miriam Elfström; Sven-Erik Olsson; Joakim Dillner; Sonia Andersson
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities.

Authors:  M Fröberg; B Johansson; A Hjerpe; S Andersson
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

9.  Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study.

Authors:  Maria Persson; K Miriam Elfström; Sophia Brismar Wendel; Elisabete Weiderpass; Sonia Andersson
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

10.  Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening.

Authors:  Dana Hashim; Birgit Engesæter; Gry Baadstrand Skare; Philip E Castle; Tone Bjørge; Ameli Tropé; Mari Nygård
Journal:  Br J Cancer       Date:  2020-04-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.